On April 21, 2025 Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), reported an upcoming presentation of non-clinical data for K-679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity (Press release, Kowa, APR 21, 2025, View Source [SID1234652000]). The compound, developed using Kowa’s proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Presentation Title: K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs.
Session Title: Novel Drug Delivery Technologies
Presentation Date and Time: April 28, 2025, 9:00 a.m. – 12:00 p.m. CST (10:00 a.m. – 1:00 p.m. ET)
Published Abstract Number: 1798
Presenter: Hideo Yoshida
The abstract of the presentation is available at
View Source!/20273/presentation/3006.
More information about the AACR (Free AACR Whitepaper) Annual Meeting 2025 can be found on the event website at the following link: AACR (Free AACR Whitepaper) Annual Meeting 2025 | Meetings | AACR (Free AACR Whitepaper)
About K-679
K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa’s proprietary micelle technology, currently at non-clinical stage. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 40 DM1 molecules per antibody, significantly higher than conventional ADCs.
In non-clinical studies, K-679 has demonstrated potent anti-tumor effects in xenograft models, outperforming conventional ADCs. Notably, K-679 has shown remarkable efficacy in EGFR‑positive and -negative heterogeneous tumors, exhibiting significant bystander killing effects.